Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Scientists train to dive beneath polar ice as climate change warms the Arctic and Antarctica - 2Recalled Super Greens diet supplement powder sickens 45 with salmonella
- 3Hamas propaganda expert explains Israel's internal conflicts influenced Hamas's Oct. 7 assault
- 4Doulas play essential roles in reproductive health care – and more states are beginning to recognize it
- 5Your kid wants it now. What saying yes, no or not yet teaches kids about money and instant gratification.
- Creative Tech Contraptions That Will Work on Your Life
- Free Fuel Giveaway Sparks Traffic Mayhem Before Police Shut It Down
- Members of Kenya-led security mission in Haiti were involved in rapes, U.N. says
- The Green Transformation: 5 Feasible Living Practices
- Moscow: Russia well-positioned to withstand oil market shocks
- Five killed in Israeli air strikes on tents near Khan Younis, medics say
- Support Your Body: A Manual for Smart dieting and Sustenance
- Israel and Lebanon's Hezbollah continue to trade attacks
- If you want a true taste of Italian paradise, head to Favignana
